GlassScriptPhysician profile
Anthony P Bucolo
NPI 1497752638
$8,844.66
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $912 · 2021: $1,999 · 2022: $2,819 · 2023: $2,949 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.09 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $795.50 | 2020-2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $676.69 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $638.00 | 2020-2023 | Enhertu, Imfinzi, Tagrisso |
| Lilly USA, LLC | $552.76 | 2020-2023 | Jaypirca, Retevmo, Verzenio |
| Seagen INC. | $519.99 | 2020-2023 | Adcetris, Tukysa |
| Janssen Biotech, INC. | $506.51 | 2020-2023 | Darzalex, Imbruvica, Symtuza |
| Celgene Corporation | $481.35 | 2020-2023 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $442.19 | 2021-2023 | |
| Incyte Corporation | $348.92 | 2020-2023 | Jakafi, Monjuvi |
| Beigene USA, INC. | $287.79 | 2020-2023 | Brukinsa |
| Genzyme Corporation | $254.73 | 2020-2023 | |
| Genentech USA, INC. | $236.17 | 2022-2023 | Tecentriq, Lunsumio, Venclexta |
| Exelixis INC. | $201.93 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $182.15 | 2022-2023 | Opdivo, Opdualag |
| Astellas Pharma US INC | $144.99 | 2022-2023 | Padcev, Xospata |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Bucolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.